Emcure Unit Acquires Mantra Pharma Shares for CAD 50 Million (Approx. ₹336 Crore)
Marcan Pharmaceuticals Inc., a subsidiary of Emcure Pharmaceuticals, has acquired 100% of the Class E Special Shares in Mantra Pharma Inc. for CAD 50 million (approximately ₹336 crore), finalised on July 03, 2026. Mantra, incorporated in Quebec, Canada, is engaged in marketing and distributing prescription drugs and natural health products, reporting a turnover of CAD 96.67 million in FY2026. The transaction is exempt from related party transaction norms under SEBI regulations and was conducted at arm's length.
*this image is generated using AI for illustrative purposes only.
Marcan Pharmaceuticals Inc., a subsidiary of Emcure Pharmaceuticals , has acquired 100% of the Class E Special Shares in its step-down subsidiary Mantra Pharma Inc. for an aggregate cash consideration of CAD 50 million (approximately ₹336 crore). The acquisition, executed through share purchase agreements on July 02, 2026, ensures that Mantra continues to be a wholly-owned subsidiary of Marcan. This strategic move consolidates control over the Canadian entity, which reported an annual turnover of CAD 96.67 million for the financial year 2026. The acquisition was finalized on July 03, 2026.
Transaction Structure and Regulatory Compliance
The transaction constitutes a related party transaction between two wholly-owned subsidiaries but is exempt under Regulation 23(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The deal was undertaken at arm's length, and no specific government approvals were required beyond the completion of requisite compliances under applicable laws in Canada.
About Mantra Pharma Inc.
Mantra Pharma Inc. is incorporated under the laws of Quebec, Canada, and is engaged in the marketing and distribution of prescription drugs and natural health products. The entity was formed on November 06, 2023, through an amalgamation of several companies. Its capital structure consists of 1,000 Class A Common Shares and 24,000,000 Class E Special Shares without par value.
Key Deal Parameters
The following table summarises the key details of the acquisition:
| Parameter: | Details |
|---|---|
| Acquirer: | Marcan Pharmaceuticals Inc. |
| Target: | Mantra Pharma Inc. |
| Consideration: | CAD 50 million (approx. ₹336 crore) |
| Stake Acquired: | 100% Class E Special Shares |
| Agreement Date: | July 02, 2026 |
| Completion Date: | July 03, 2026 |
| Incorporation: | Quebec, Canada |
Financial Performance of Mantra Pharma Inc.
The financial performance of Mantra has shown significant growth over the last three financial years. The aggregate historical turnover for the period ending March 31, 2026, reflects a steady increase in business operations within the Canadian market.
| Financial Year: | Turnover (CAD) |
|---|---|
| 2026 | 96.67 million |
| 2025 | 81.01 million |
| 2024* | 28.26 million |
*For the period November 06, 2023 till March 31, 2024.
Historical Stock Returns for Emcure Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.86% | -2.11% | +7.99% | +28.63% | +44.86% | +35.42% |
How will the CAD 50 million cash outflow impact Emcure Pharmaceuticals' capital allocation strategy for upcoming fiscal years?
Does full consolidation of Mantra Pharma signal a shift in Emcure's strategy towards direct control rather than joint ventures in international markets?
What are the projected revenue synergies or cost savings expected from this vertical integration of the Canadian marketing and distribution arm?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
